Core Viewpoint - Hainan Haiyao's stock price has shown volatility, with a recent decline of 2.99% and a year-to-date increase of 28.60%, indicating mixed investor sentiment and market performance [1][2]. Company Performance - As of October 31, Hainan Haiyao reported a revenue of 640 million yuan for the first nine months of 2025, a year-on-year decrease of 20.51%, while the net profit attributable to shareholders was -24.2 million yuan, reflecting a growth of 17.91% compared to the previous year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 466 million yuan since its A-share listing [3]. Stock Market Activity - The stock has experienced a 0.81% decline over the last five trading days and a 12.82% increase over the past 20 days, with a 2.84% decrease over the last 60 days [2]. - Hainan Haiyao has appeared on the stock market's "龙虎榜" three times this year, with the most recent appearance on June 3 [2]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 2.47% to 75,600, while the average number of circulating shares per person increased by 2.53% to 15,420 shares [2]. - The seventh largest circulating shareholder is Hong Kong Central Clearing Limited, holding 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]. Business Overview - Hainan Haiyao, established on December 30, 1992, and listed on May 25, 1994, operates in the pharmaceutical sector, focusing on traditional and Western medicine, fine chemicals, chemical raw materials, health products, and related import-export trade [2]. - The company's revenue composition includes 29.93% from other products, 25.07% from gastrointestinal products, 18.60% from medical services, 13.27% from raw materials and intermediates, and 10.19% from cephalosporin series [2]. Industry Context - Hainan Haiyao is categorized under the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and chemical preparation sectors, and is associated with concepts such as Hainan Free Trade Zone, private hospitals, low-priced stocks, small-cap stocks, and state-owned enterprise reforms [2].

Core Viewpoint - Hainan Haiyao's stock price has shown a significant increase this year, with a 25.47% rise, despite a recent decline over the past 60 days [1][2] Group 1: Stock Performance - As of October 31, Hainan Haiyao's stock price reached 6.01 CNY per share, with a market capitalization of 7.797 billion CNY [1] - The stock has experienced a 5.07% increase over the last five trading days and a 9.07% increase over the last 20 trading days, while it has decreased by 6.39% over the last 60 days [1] - The company has appeared on the stock market's "龙虎榜" three times this year, with the latest occurrence on June 3 [1] Group 2: Financial Performance - For the period from January to September 2025, Hainan Haiyao reported a revenue of 640 million CNY, representing a year-on-year decrease of 20.51%, while the net profit attributable to shareholders was -242 million CNY, showing a year-on-year increase of 17.91% [2] - The company has cumulatively distributed 466 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Group 3: Shareholder Information - As of October 20, the number of shareholders for Hainan Haiyao increased by 4.70% to 77,500, while the average number of circulating shares per person decreased by 4.49% to 15,040 shares [2] - As of September 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 6.6464 million shares, a decrease of 1.1481 million shares from the previous period [3]